VIDA
Modernizing Lung and Respiratory Care
Modernizing Lung and Respiratory Care
VIDA is a clinical imaging intelligence company that is accelerating the approval and adoption of life-saving therapies to patients through an AI-powered digital biomarker solution. With proprietary imaging biomarkers for precise quantitative endpoints and a trial imaging management solution, VIDA’s solution is helping biopharma sponsors save millions in drug development costs. The company, founded in 2004, operates in the Biotechnology and Health Care industries and is based in the United States. VIDA recently secured a $10.82M Venture Round investment on 29 September 2023. This funding round will likely enable the company to further develop its AI-powered digital biomarker solution and expand its reach within the biopharmaceutical industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $10.82M | - | 29 Sep 2023 | |
| Series C | $2.00M | 1 | OSF Ventures | 15 Apr 2020 |
| Series C | $11.00M | 9 |
|
12 Mar 2020 |
| Corporate Round | $1.00M | 1 |
|
25 Jul 2019 |
| Debt Financing | $500.00K | 1 | Iowa Innovation Acceleration Fund | 21 May 2019 |
No recent news or press coverage available for VIDA.
We care about your data, and we'd love to use cookies make your experience better.
